Find information on thousands of medical conditions and prescription drugs.

Ticlopidine

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Probable interaction between cyclosporin A and low dose ticlopidine
From British Medical Journal, 4/15/00

We report on a probable interaction between ticlopidine 250 mg once daily and cyclosporin A leading to a decrease in the trough concentration dose ratio--that is, concentration divided by daily dose per kilogram--of cyclosporin A.

A 64 year old woman had a stable renal graft. She was given ticlopidine 250 mg once daily owing to a left third cranial nerve palsy of new onset probably caused by ischaemia. Relevant medical history after the transplant included diabetes mellitus and angina precipitated by supraventricular tachycardia. The patient was taking frusemide (furosemide), digoxin, insulin, prednisone, azathioprine, and cyclosporin A throughout follow up. The patient was given pravastatin from 1132 to 1279 days after transplantation.

The dose of cyclosporin A was changed several times during the three year follow up (range 2.81-4.39 mg/kg daily). We therefore report the results as the concentration dose ratio, which gives an approximation of the clearance and bioavailability of the drug.

Monitoring of cyclosporin A concentration in whole blood by an enzyme multiplied immunoassay technique (EMIT 200, Behring Diagnostics, Cupertino, CA) showed a decrease in concentration dose ratio after ticlopidine was introduced. The median concentration dose ratios were 36 before and 25 after treatment with ticlopidine. The patient agreed to stop taking ticlopidine for three months, and aspirin 200 mg/day was simultaneously added to the treatment. The median concentration dose ratios were 38 and 26 after the discontinuation and reintroduction of ticlopidine (figure). No signs of graft rejection were observed.

[Figure ILLUSTRATION OMITTED]

We considered ticlopidine to be responsible for the observed changes because of both the observed temporal sequence, including the effects of reintroduction and with drawal of ticlopidine, and the history of an interaction with ticlopidine 500 mg daily.[1 2]

The only previous published report evaluating the potential interactions between ticlopidine and cyclosporin A, with half standard doses of ticlopidine for 14 days in 20 recipients of heart transplants, failed to show clear evidence of any pharmacokinetic modification.[3] We found that ticlopidine 250 mg once daily decreased the blood concentration of cyclosporin A in this patient, and we would therefore recommend close monitoring of such blood concentrations when introducing or withdrawing ticlopidine in patients taking cyclosporin A.

[1] Birmele B, Lebranchu Y, Bagros Ph, Nivet H, Furet Y, Pengloan J. Interaction of cyclosporin and ticlopidine. Nephrol Dial Transplant 1991;6:150-1.

[2] De Lorgeril M, Boissonat P, Dureau G, GuidolletJ, Renaud S. Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. Transplantation 1993;55:1195-6.

[3] Boissonat P, de Lorgeril M, Perroux V, Salen P, Batt AM, BarthelemyJC, et al. A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients. Eur J Clin Pharmacol 1997;53:39-45.

A Verdejo, M A de Cos,J A Zubimendi, Services of Clinical Pharmacology and Nephrology, Marques de Valdecilla University Hospital, E-39008 Santander, Spain, L Lopez-Lazaro, Clinical Pharmacology Service, San Carlos Hospital, E-28040 Madrid, Spain

COPYRIGHT 2000 British Medical Association
COPYRIGHT 2000 Gale Group

Return to Ticlopidine
Home Contact Resources Exchange Links ebay